Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB 3-Year Dividend Growth Rate?

Infant Bacterial Therapeutics AB's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The historical rank and industry rank for Infant Bacterial Therapeutics AB's 3-Year Dividend Growth Rate or its related term are showing as below:

IFTBF's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Infant Bacterial Therapeutics AB's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00. As of today, Infant Bacterial Therapeutics AB's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Infant Bacterial Therapeutics AB's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's 3-Year Dividend Growth Rate falls into.

Infant Bacterial Therapeutics AB 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Infant Bacterial Therapeutics AB (GREY:IFTBF) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Infant Bacterial Therapeutics AB's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2024 )	/	EPS without NRI (Q: Mar. 2024 )
	=	0	/	-0.198
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB 3-Year Dividend Growth Rate Related Terms>

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

IBT B:Sweden 9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines